SHPHF (Sihuan Pharmaceutical Holdings Group) EBIT per Share: $0.01 (TTM As of Dec. 2025)


SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
52 GF Score
Price $0.13
GF Value $0.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group EBIT per Share?

Sihuan Pharmaceutical Holdings Group SHPHF 52 EBIT per Share is $0.01 as of Dec. 2025. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks worse than 123304.44% on this metric.

Sihuan Pharmaceutical Holdings Group's EBIT per Share for the six months ended in Dec. 2025 was $0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sihuan Pharmaceutical Holdings Group was 70.40% per year. The lowest was -31.90% per year. And the median was 24.30% per year.

SHPHF's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sihuan Pharmaceutical Holdings Group's EBIT for the six months ended in Dec. 2025 was $50.7 Mil.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Sihuan Pharmaceutical Holdings Group EBIT per Share Related Terms


Sihuan Pharmaceutical Holdings Group EBIT per Share Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group EBIT per Share Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.03 0.00 -0.00 0.01

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.01
SHPHF
52GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sihuan Pharmaceutical Holdings Group's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=87.848/9126.832
=0.01

Sihuan Pharmaceutical Holdings Group's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=50.664/9049.652
=0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $0.01 mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a EBIT per Share of $0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Sihuan Pharmaceutical Holdings Group's EBIT per Share too high?
Sihuan Pharmaceutical Holdings Group's current EBIT per Share is $0.01. The Drug Manufacturers industry median EBIT per Share is 7.80. Sihuan Pharmaceutical Holdings Group's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #999999 out of 811 companies for EBIT per Share. This places Sihuan Pharmaceutical Holdings Group in the lower half of its industry. The industry median EBIT per Share is 7.80. Sihuan Pharmaceutical Holdings Group's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current EBIT per Share of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current EBIT per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.13 — trading 23.7% below its estimated fair value. The current EBIT per Share is $0.01 and 99.9% below the Drug Manufacturers industry median of 7.80. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current EBIT per Share is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.13 is trading 23.7% below its estimated GF Value™ of $0.17. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • EBIT per Share: $0.01
  • GF Value™: $0.17 vs. price of $0.13 (23.7% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 99.9% below the Drug Manufacturers median (#999999 of 811)

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score

Get the complete analysis for SHPHF

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.17
GF Value